TargetMol

F-14512 (free base)

Product Code:
 
TAR-T27299
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T27299-5mg5mg£850.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T27299-50mg50mg£1,661.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T27299-100mg100mg£2,079.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
F-14512, a DNA topoisomerase II inhibitor, is used potentially for the treatment of acute myeloid leukemia.
CAS:
866874-63-7
Formula:
C33H47N5O8
Molecular Weight:
641.766
Purity:
0.98
SMILES:
[H][C@]12COC(=O)[C@]1([H])[C@H](c1cc(OC)c(O)c(OC)c1)c1cc3OCOc3cc1[C@H]2NC(=O)CNCCCNCCCCNCCCN

References

1. Tierny D, Serres F, Segaoula Z, Bemelmans I, Bouchaert E, P?tain A, Brel V, Couffin S, Marchal T, Nguyen L, Thuru X, Ferr? P, Guilbaud N, Gomes B. Phase I Clinical Pharmacology Study of F14512, a New Polyamine-Vectorized Anticancer Drug, in Naturally Occurring Canine Lymphoma. Clin Cancer Res. 2015 Dec 1;21(23):5314-23. doi: 10.1158/1078-0432.CCR-14-3174. PubMed PMID: 26169968. 2. Mouawad F, Gros A, Rysman B, Bal-Mahieu C, Bertheau C, Horn S, Sarrazin T, Lartigau E, Chevalier D, Bailly C, Lansiaux A, Meignan S. The antitumor drug F14512 enhances cisplatin and ionizing radiation effects in head and neck squamous carcinoma cell lines. Oral Oncol. 2014 Feb;50(2):113-9. doi: 10.1016/j.oraloncology.2013.11.003. PubMed PMID: 24290982. 3. Leblond P, Boulet E, Bal-Mahieu C, Pillon A, Kruczynski A, Guilbaud N, Bailly C, Sarrazin T, Lartigau E, Lansiaux A, Meignan S. Activity of the polyamine-vectorized anti-cancer drug F14512 against pediatric glioma and neuroblastoma cell lines. Invest New Drugs. 2014 Oct;32(5):883-92. doi: 10.1007/s10637-014-0132-3. PubMed PMID: 25008900. 4. Thibault B, Clement E, Zorza G, Meignan S, Delord JP, Couderc B, Bailly C, Narducci F, Vandenberghe I, Kruczynski A, Guilbaud N, Ferr? P, Annereau JP. F14512, a polyamine-vectorized inhibitor of topoisomerase II, exhibits a marked anti-tumor activity in ovarian cancer. Cancer Lett. 2016 Jan 1;370(1):10-8. doi: 10.1016/j.canlet.2015.09.006. PubMed PMID: 26404751.